• Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast
ABOUT
Advertise in GAT
Contact us
Friday, January 27, 2023
Georgia Asian Times
International Insurance of Georgia
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast
  • Login
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast
No Result
View All Result
Georgia Asian Times
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
Home Coronavirus

Pfizer ends vaccine trial with 95% success rate, paving way for a shot this year

Georgia Asian Times by Georgia Asian Times
November 18, 2020
in Coronavirus, Headline, Health
Share on FacebookShare on Twitter

New York, Nov 18, 2020 – Final results from Pfizer Inc’s COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The vaccine’s efficacy rate, the highest of any candidate in late-stage clinical trials so far, was welcomed by experts who had already said that interim results showing Pfizer’s shot was over 90% effective were very encouraging.

Pfizer said there were 170 cases of COVID-19 in its trial of more than 43,000 volunteers and only eight people with the disease had been given the shot rather than a placebo, meaning the vaccine had a 95% efficacy rate. Of the 10 people who developed severe COVID-19, one had received the vaccine.

“The data is very strong,” said Ian Jones, a professor of virology at Britain’s University of Reading. “It’s looking like a real contender.”

AD: High Museum of Atlanta

Pfizer said it expected the U.S. Food and Drug Administration’s vaccine advisory committee to review and discuss the data in a public meeting that will likely be held in December.

“We continue to move at the speed of science, and we know that every day matters in our path to authorization,” Pfizer Chief Executive Albert Bourla said.

The final analysis comes just a week after initial results from the trial showed the vaccine, developed with German partner BioNTech SE, was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing 94.5% effectiveness.

The better-than-expected results from the two vaccines, both developed with new messenger RNA (mRNA) technology, have raised hopes for an end to a pandemic that has killed more than 1.3 million people and wreaked havoc upon economies and daily life.

However, while some groups such as healthcare workers will be prioritized in the United States for vaccinations this year, it will be months before large-scale rollouts begin.


THE MOST VULNERABLE

Distribution of a Pfizer shot is complicated by the need to store it at ultra-cold temperatures of -70 degrees Celsius. It can, however, be kept in a normal fridge for up to five days, or up to 15 days in a thermal shipping box.

Q&A: Where are we in the COVID-19 vaccine race?

Pfizer said the efficacy of the vaccine was consistent across different age and ethnic groups, a sign that the immunization could be employed broadly around the world.

Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.

“The 94% protection for older people is key. This is the evidence we needed to ensure that the most vulnerable people are protected,” said Andrew Hill, senior visiting research fellow at the University of Liverpool’s department of pharmacology.

Equity markets strengthened slightly on the Pfizer news. Europe’s STOXX 600 and the U.S S&P 500 futures both rose about 0.3% to hit highs for the day. The moves were small, however, compared with the jump when Pfizer first announced the vaccine was more than 90% effective on Nov. 9.

Pfizer shares rose 3% in premarket trade while BioNTech’s U.S.-listed shares jumped 8%.

 

MILD SIDE EFFECTS

Pfizer said its two-dose vaccine, BNT162b2, was well-tolerated and that side effects were mostly mild to moderate, and cleared up quickly.

The only severe adverse event that affected more than 2% of those vaccinated was fatigue, which affected 3.7% of recipients after the second dose. Older adults tended to report fewer and milder adverse events.

Moderna named five categories of severe side effects experienced by at least 2% of those who received its vaccine. It listed fatigue at a frequency of 9.7%, muscle pain at 8.9%, joint pain at 5.2%, headache at 4.5%, pain at 4.1% and redness around the injection site at 2%.

Pfizer’s final results come as the virus is running rampant around the world, placing an enormous strain on healthcare systems with record numbers of new cases and hospitalizations.

The approach of winter in the northern hemisphere in tandem with the holiday season is expected to worsen case numbers as people spend more time indoors and have family gatherings.

“With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” Pfizer’s Bourla said.

Pfizer and BioNTech also said they plan to submit the data to other regulatory agencies around the world and submit data from the study to a peer-reviewed scientific journal.

Pfizer reiterated that it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

Of the dozens of drugmakers and research groups racing to develop vaccines against COVID-19, the next data release will likely be from AstraZeneca Plc with the University of Oxford in November or December. Johnson & Johnson says it is on track to deliver data this year. – Reuters

 

Previous Post

Bitcoin breaks $18,000 with all-time high in sight

Next Post

As U.S. Senate battle intensifies in Georgia, allegations fly

Georgia Asian Times

Georgia Asian Times

Related Posts

You’ll likely be happier if your home follows the ‘3-30-300 rule’
Health

You’ll likely be happier if your home follows the ‘3-30-300 rule’

December 22, 2022
Limited English Proficiency a Major Access Barrier to Healthcare for AAPIs, according to study
Health

Limited English Proficiency a Major Access Barrier to Healthcare for AAPIs, according to study

December 14, 2022
Hospitalizations signal rising COVID-19 risk for US seniors
Health

Hospitalizations signal rising COVID-19 risk for US seniors

December 11, 2022
Low costs expected to keep Obamacare interest high
Health

Low costs expected to keep Obamacare interest high

October 31, 2022
Health

COVID-19 Updated Booster Vaccines Covered Without Cost-Sharing for Eligible Children Ages 5 to 11

October 24, 2022
Trial over Georgia’s restrictive abortion law to begin
Health

Trial over Georgia’s restrictive abortion law to begin

October 24, 2022
Next Post

As U.S. Senate battle intensifies in Georgia, allegations fly

Signup Free E-Newsletter

Upcoming Events

Jan 28
1:00 pm - 5:00 pm

Decatur Lunar New Year Festival

Jan 28
3:30 pm - 4:30 pm

Chinese New Year Celebration-Chamblee

Feb 18
6:00 pm - 11:00 pm

Spring Festival 2023

View Calendar
Logo

 

CONTACT US

Follow Us

MOST INFLUENTIAL

GAT 25 Most Influential Asian Americans Gala celebrates Asian voice

GAT 25 Most Influential Asian Americans Gala celebrates Asian voice

July 18, 2022

Video highlights of GAT 25 Most Influential Asian Americans in Georgia

July 17, 2022

2022 GAT 25 Most Influential Asian Americans in Georgia-Awards Gala

July 17, 2022

LINKS OF INTEREST

ATL Asian Film Festival

GAT on Facebook

Lunar New Year of Rabbit - GAT Special Section
  • Contact Us
  • Advertise in GAT
  • ABOUT

© 2023 Georgia Asian Times - Empowered by 8SOL. Managed by Arckopolis.

No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Tam Su Voi
    • Usapang Pinoy
    • GAT Insight
    • Georgia Korean Podcast

© 2023 Georgia Asian Times - Empowered by 8SOL. Managed by Arckopolis.

Welcome Back!

Sign In with Google
OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe

Subscribe to our newsletter for the latest
articles straight to your inbox!

    Are you sure want to unlock this post?
    Unlock left : 0
    Are you sure want to cancel subscription?